Summary of key Information: Oral Semaglutide (Rybelsus) & GLP-1/GIP Receptor Agonists
This document provides an update on oral semaglutide (Rybelsus) and its place within the broader landscape of GLP-1 and GLP-1/GIP receptor agonists for type 2 diabetes management. Here’s a breakdown of the key takeaways:
1. Increased Use & Potential Transitions:
* The recent FDA approval of oral semaglutide for cardiovascular risk reduction is likely to increase its use.
* There may be a shift of patients from injectable semaglutide (Ozempic, Wegovy) and other GLP-1/GIP agonists (Mounjaro, Zepbound, Trulicity, victoza, Saxenda) to oral semaglutide.
2. Transitioning Patients to Oral Semaglutide:
* From Injectable Semaglutide (0.5mg): Patients can transition to oral semaglutide (R1 formulation) at 7 or 14mg, starting one week after their last injection.
* From Other Injectable GLPs: Transition can be based on comparative dosing information from studies, but further data is needed.
3. Oral Semaglutide Formulations:
* There are two formulations of oral semaglutide: R1 and R2. Currently, more data is needed to determine if the R2 formulation will have similar benefits to R1.
4. Patient Education Needs:
* Healthcare professionals may need additional training on the proper governance of various GLP-1 and GIP receptor agonists (including injectable vs. oral forms, and specific dosing/timing requirements).
5. patient Preferences:
* Studies suggest some patients prefer oral medications over injectables (Boye et al., 2021).
* Adherence might potentially be better wiht oral semaglutide compared to injectable semaglutide (Horii et al., 2024).
6. supply Considerations:
* The document acknowledges potential shortages of GLP-1 and GLP-1/GIP agonists and suggests strategies for addressing them (Whitley et al., 2023).
Resources Referenced:
The document references prescribing information for several medications (Rybelsus, Trulicity, Saxenda, Victoza, Mounjaro, Zepbound, Ozempic, wegovy) and includes links to:
* FDA press release regarding oral semaglutide approval.
* Relevant studies published in New England Journal of Medicine and Diabetes obesity and Metabolism.
Date of Information:
The information is current as of October 30, 2025 (based on the access dates of the referenced materials).
